
Verantos is collaborating with Amgen to study patients with severe asthma and the use of biologics, including Tezspire, through the Asthma Pragmatic Registry. Composed of real-world data collected from academic and community health systems, the Asthma Pragmatic Registry provides a view of the patient journey, including disease severity, treatment, symptom control, resource utilization and clinical outcome parameters.
The Asthma Pragmatic Registry is supported by the FDA demonstration project, Transforming Real-World Evidence With Unstructured and Structured Data to Advance Tailored Therapy, or TRUST.
"We are excited to expand our collaboration with Verantos and help contribute to improvements in high-quality, real-world data collection," said Brian Bradbury, vice president of observational research at Amgen. "By gathering and curating this data on patients with severe asthma to support principled real-world evidence generation, Amgen will gain an even deeper understanding into the patient experience, journey and outcomes."
Pragmatic Registry is a recently launched high-validity product that addresses limitations in existing registry solutions. Pragmatic registries, created from routinely collected data, have several benefits over traditional patient registries. They offer flexibility, scalability and data on health care resource utilization. By utilizing advanced RWE-generation methods, Pragmatic Registry meets the exacting evidentiary standard of accuracy, completeness and traceability while offering a detailed and credible view into the patient journey.